A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs

Georgina B F Hall; Rachael Birkbeck; Benjamin M Brainard; Fernanda Camacho; Elizabeth B Davidow; Dana N LeVine; Andrew Mackin; Taylor Moss; Katherine J Nash; Giacomo Stanzani; Daria Starybrat; David Q Stoye; Carolyn Tai; John Thomason; Julie M Walker; K Jane Wardrop; Helen Wilson; Virginie A Wurlod; Karen Humm

doi:10.1111/jvim.17175

A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs

Georgina B F Hall, Rachael Birkbeck, Benjamin M Brainard, Fernanda Camacho, Elizabeth B Davidow, Dana N LeVine, Andrew Mackin, Taylor Moss, Katherine J Nash, Giacomo Stanzani, Daria Starybrat, David Q Stoye, Carolyn Tai, John Thomason, Julie M Walker, K Jane Wardrop, Helen Wilson, Virginie A Wurlod, Karen Humm

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

BACKGROUND: Reported incidence of blood transfusion reactions (TR) varies greatly.

OBJECTIVE: To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.

ANIMALS: Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.

METHODS: Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.

RESULTS: The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).

CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.

Original language	English
Pages (from-to)	2495-2506
Number of pages	12
Journal	Journal of Veterinary Internal Medicine
Volume	38
Issue number	5
Early online date	6 Sept 2024
DOIs	https://doi.org/10.1111/jvim.17175
Publication status	Published - 2024

Keywords / Materials (for Non-textual outputs)

Animals
Australia/epidemiology
Blood Transfusion/veterinary
Dog Diseases/epidemiology
Dogs
Erythrocyte Transfusion/veterinary
Female
Incidence
Male
Prospective Studies
Risk Factors
Transfusion Reaction/veterinary
United Kingdom/epidemiology
United States/epidemiology

Access to Document

10.1111/jvim.17175

Veterinary Internal Medicne - 2024 - Hall - A prospective multicenter observational study assessing incidence and riskFinal published version, 864 KBLicence: Creative Commons: Attribution (CC-BY)

Cite this

Hall, G. B. F., Birkbeck, R., Brainard, B. M., Camacho, F., Davidow, E. B., LeVine, D. N., Mackin, A., Moss, T., Nash, K. J., Stanzani, G., Starybrat, D., Stoye, D. Q., Tai, C., Thomason, J., Walker, J. M., Wardrop, K. J., Wilson, H., Wurlod, V. A., & Humm, K. (2024). A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs. Journal of Veterinary Internal Medicine, 38(5), 2495-2506. https://doi.org/10.1111/jvim.17175

@article{d670db4c62f541ce9ce029a2658e75fb,

title = "A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs",

abstract = "BACKGROUND: Reported incidence of blood transfusion reactions (TR) varies greatly.OBJECTIVE: To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.ANIMALS: Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.METHODS: Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.RESULTS: The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.",

keywords = "Animals, Australia/epidemiology, Blood Transfusion/veterinary, Dog Diseases/epidemiology, Dogs, Erythrocyte Transfusion/veterinary, Female, Incidence, Male, Prospective Studies, Risk Factors, Transfusion Reaction/veterinary, United Kingdom/epidemiology, United States/epidemiology",

author = "Hall, {Georgina B F} and Rachael Birkbeck and Brainard, {Benjamin M} and Fernanda Camacho and Davidow, {Elizabeth B} and LeVine, {Dana N} and Andrew Mackin and Taylor Moss and Nash, {Katherine J} and Giacomo Stanzani and Daria Starybrat and Stoye, {David Q} and Carolyn Tai and John Thomason and Walker, {Julie M} and Wardrop, {K Jane} and Helen Wilson and Wurlod, {Virginie A} and Karen Humm",

note = "{\textcopyright} 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.",

year = "2024",

doi = "10.1111/jvim.17175",

language = "English",

volume = "38",

pages = "2495--2506",

journal = "Journal of Veterinary Internal Medicine",

issn = "0891-6640",

publisher = "Wiley-Blackwell",

number = "5",

}

Hall, GBF, Birkbeck, R, Brainard, BM, Camacho, F, Davidow, EB, LeVine, DN, Mackin, A, Moss, T, Nash, KJ, Stanzani, G, Starybrat, D, Stoye, DQ, Tai, C, Thomason, J, Walker, JM, Wardrop, KJ, Wilson, H, Wurlod, VA & Humm, K 2024, 'A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs', Journal of Veterinary Internal Medicine, vol. 38, no. 5, pp. 2495-2506. https://doi.org/10.1111/jvim.17175

TY - JOUR

T1 - A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs

AU - Hall, Georgina B F

AU - Birkbeck, Rachael

AU - Brainard, Benjamin M

AU - Camacho, Fernanda

AU - Davidow, Elizabeth B

AU - LeVine, Dana N

AU - Mackin, Andrew

AU - Moss, Taylor

AU - Nash, Katherine J

AU - Stanzani, Giacomo

AU - Starybrat, Daria

AU - Stoye, David Q

AU - Tai, Carolyn

AU - Thomason, John

AU - Walker, Julie M

AU - Wardrop, K Jane

AU - Wilson, Helen

AU - Wurlod, Virginie A

AU - Humm, Karen

PY - 2024

Y1 - 2024

N2 - BACKGROUND: Reported incidence of blood transfusion reactions (TR) varies greatly.OBJECTIVE: To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.ANIMALS: Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.METHODS: Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.RESULTS: The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.

AB - BACKGROUND: Reported incidence of blood transfusion reactions (TR) varies greatly.OBJECTIVE: To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.ANIMALS: Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.METHODS: Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.RESULTS: The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.

KW - Animals

KW - Australia/epidemiology

KW - Blood Transfusion/veterinary

KW - Dog Diseases/epidemiology

KW - Dogs

KW - Erythrocyte Transfusion/veterinary

KW - Female

KW - Incidence

KW - Male

KW - Prospective Studies

KW - Risk Factors

KW - Transfusion Reaction/veterinary

KW - United Kingdom/epidemiology

KW - United States/epidemiology

U2 - 10.1111/jvim.17175

DO - 10.1111/jvim.17175

M3 - Article

C2 - 39239720

SN - 0891-6640

VL - 38

SP - 2495

EP - 2506

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

IS - 5

ER -

A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this